Cohen Investment Advisors’s GSK GSK Stock Holding History

Cohen Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,616	Closed	-$349K	–	78
2024 Q2	$349K	Buy	+9,616	New	+$404K	0.28%	68
2023 Q4	–	Sell	-9,616	Closed	-$349K	–	77
2023 Q3	$349K	Sell	9,616 -295	-3%	-$10.5K	0.28%	68
2023 Q2	$353K	Buy	9,911 +46	+0.5%	+$1.65K	0.28%	70
2023 Q1	$351K	Buy	9,865 +765	+8%	+$26.8K	0.28%	72
2022 Q4	$320K	Buy	9,100 +868	+11%	+$28.9K	0.27%	70
2022 Q3	$242K	Buy	8,232 +262	+3%	+$9.93K	0.22%	73
2022 Q2	$434K	Buy	7,970 +116	+1%	+$6.4K	0.37%	59
2022 Q1	$428K	Buy	7,854 +100	+1%	+$5.43K	0.32%	67
2021 Q4	$427K	Buy	7,754 +63	+0.8%	+$3.28K	0.3%	63
2021 Q3	$367K	Buy	7,691 +41	+0.5%	+$2.06K	0.28%	71
2021 Q2	$381K	Buy	7,650 +67	+0.9%	+$3.22K	0.3%	69
2021 Q1	$338K	Buy	7,583 +132	+2%	+$5.99K	0.27%	74
2020 Q4	$343K	Buy	+7,451	New	+$342K	0.31%	69

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cohen Investment Advisors's GSK Position: Q3 2024 in Review

Cohen Investment Advisors sold out of GSK (GSK) in Q3 2024, closing a stake of 9,616 shares — an estimated $349K sold.

Cohen Investment Advisors first reported a position in GSK in Q4 2020 and held it in 13 quarters. The position peaked at $434K in Q2 2022. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Cohen Investment Advisors reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Cohen Investment Advisors sold 9,616 GSK shares in Q3 2024, an estimated $349K.
Cohen Investment Advisors first reported a position in GSK in Q4 2020 and held it in 13 quarters.
Cohen Investment Advisors's GSK position peaked at $434K in Q2 2022.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Cohen Investment Advisors's 13F filing for Q3 2024, filed 7 Oct 2024.